Medical News / Directly from ESC 2023: Acoramidis Reduces All-Cause, Cardiovascular Mortality at 30 Months in ATTR-CM

The 30-month results of the phase 3 ATTRibute-CM trial provide the latest insight into the effects of acoramidis in people with transthyretin amyloid cardiomyopathy (ATTR-CM) ahead of a potential regulatory submission for the agent. Presented during a hot line session at the European Society of Cardiology (ESC) Congress 2023, results of the trial suggest the acoramidis cohort experienced an 81% survival rate at 30 months, with additional analysis suggesting use of acoramidis was associated with a 30% reduction in risk of cardiovascular death relative to placebo therapy. Source: MDMag. To view the third party content, kindly click on the link below or read more. You will then leave this site and enter a third party site.

read more

Data from an analysis of the landmark CLEAR Outcomes trial suggests bempedoic acid could prove useful ... read more
At the European Society of Cardiology (ESC) Congress 2023, the spotlight was on mavacamten and its ... read more
Data from VALOR-HCM LTE suggest use of the cardiac myosin inhibitor mavacamten (Camzyos) could reduce the ... read more
For frail elderly patients with atrial fibrillation, switching from a vitamin K antagonist (VKA) treatment to ... read more